Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Review article: therapeutic aspects of bile acid signalling in the gut‐liver axis
Benedikt Simbrunner, Michael Trauner, Thomas Reiberger
Alimentary Pharmacology & Therapeutics (2021) Vol. 54, Iss. 10, pp. 1243-1262
Open Access | Times Cited: 69

Showing 1-25 of 69 citing articles:

Gut–liver axis: barriers and functional circuits
Oliver Pabst, Mathias W. Hornef, Frank G. Schaap, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 7, pp. 447-461
Closed Access | Times Cited: 147
Crosstalk between bile acid-activated receptors and microbiome in entero-hepatic inflammation
Morgane M. Thibaut, Laure B. Bindels
Trends in Molecular Medicine (2022) Vol. 28, Iss. 3, pp. 223-236
Closed Access | Times Cited: 97
Gut liver brain axis in diseases: the implications for therapeutic interventions
Mengyao Yan, Shuli Man, Benyue Sun, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 73
Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options
Christoph Grander, Felix Grabherr, Herbert Tilg
Cardiovascular Research (2023) Vol. 119, Iss. 9, pp. 1787-1798
Open Access | Times Cited: 70
FXR agonists in NASH treatment
Luciano Adorini, Michael Trauner
Journal of Hepatology (2023) Vol. 79, Iss. 5, pp. 1317-1331
Open Access | Times Cited: 46
Recent advances on FXR-targeting therapeutics
Katrin Panzitt, Gernot Zollner, Hanns‐Ulrich Marschall, et al.
Molecular and Cellular Endocrinology (2022) Vol. 552, pp. 111678-111678
Open Access | Times Cited: 49
Enhancing intestinal barrier efficiency: A novel metabolic diseases therapy
Yaoyuan Zhang, Zhu Xiao, Xinyuan Yu, et al.
Frontiers in Nutrition (2023) Vol. 10
Open Access | Times Cited: 36
Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response
Benedikt Simbrunner, Esther Caparrós, Teresa Neuwirth, et al.
Hepatology International (2023) Vol. 17, Iss. 4, pp. 1045-1056
Open Access | Times Cited: 23
Recent Advances in Gut‐ and Gut–Organ‐Axis‐on‐a‐Chip Models
Raehyun Kim, Jong Hwan Sung
Advanced Healthcare Materials (2024) Vol. 13, Iss. 21
Closed Access | Times Cited: 11
Effects of Saponins on Lipid Metabolism: The Gut–Liver Axis Plays a Key Role
Shixi Cao, Mengqi Liu, Han Yao, et al.
Nutrients (2024) Vol. 16, Iss. 10, pp. 1514-1514
Open Access | Times Cited: 7
Forsythiaside A alleviated carbon tetrachloride-induced liver fibrosis by modulating gut microbiota composition to increase short-chain fatty acids and restoring bile acids metabolism disorder
Ke Fu, Cheng Ma, Cheng Wang, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 151, pp. 113185-113185
Open Access | Times Cited: 35
A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR)
Shipeng Zhou, Huimin You, Shuting Qiu, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 154, pp. 113577-113577
Open Access | Times Cited: 35
Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease
Lorenz Balcar, Julia Krawanja, Bernhard Scheiner, et al.
JHEP Reports (2023) Vol. 5, Iss. 4, pp. 100682-100682
Open Access | Times Cited: 19
Dysregulated biomarkers of innate and adaptive immunity predict infections and disease progression in cirrhosis
Benedikt Simbrunner, Lukas Hartl, Mathias Jachs, et al.
JHEP Reports (2023) Vol. 5, Iss. 5, pp. 100712-100712
Open Access | Times Cited: 16
Splenectomy ameliorates liver cirrhosis by restoring the gut microbiota balance
Ye Jin, Meixin Shi, Jing Feng, et al.
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 6
FXR-FGF19 signaling in the gut–liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence
Benedikt Simbrunner, Benedikt Hofer, Philipp Schwabl, et al.
Hepatology International (2024) Vol. 18, Iss. 3, pp. 929-942
Open Access | Times Cited: 6
Systems Theory-Driven Framework for AI Integration into the Holistic Material Basis Research of Traditional Chinese Medicine
Jingqi Zeng, Xiao‐Bin Jia
Engineering (2024) Vol. 40, pp. 28-50
Open Access | Times Cited: 5
The microbiota-derived bile acid taurodeoxycholic acid improves hepatic cholesterol levels in mice with cancer cachexia
Morgane M. Thibaut, Martin Roumain, Edwige Piron, et al.
Gut Microbes (2025) Vol. 17, Iss. 1
Open Access
Bile acid receptor FXR promotes intestinal epithelial ferroptosis and subsequent ILC3 dysfunction in neonatal necrotizing enterocolitis
Yuxin Zhang, Yuchao Jing, Juan He, et al.
Immunity (2025)
Closed Access
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease
Benedikt Simbrunner, Ida Falk Villesen, Philipp Königshofer, et al.
Liver International (2022) Vol. 42, Iss. 11, pp. 2501-2512
Open Access | Times Cited: 26
The Role of Bile Acids in Cardiovascular Diseases: from Mechanisms to Clinical Implications
Shuwen Zhang, Junteng Zhou, Wenchao Wu, et al.
Aging and Disease (2022)
Open Access | Times Cited: 25
The gut–liver axis in immune remodeling of hepatic cirrhosis
Huayu Guan, Xiang Zhang, Ming Kuang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 24
The regulation of tissue-specific farnesoid X receptor on genes and diseases involved in bile acid homeostasis
Dong Xiang, Jinyu Yang, Lu Liu, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115606-115606
Open Access | Times Cited: 15
Metabolic-Associated Fatty Liver Disease and the Gut Microbiota
Thomas M. Barber, Petra Hanson, Martin O. Weickert
Endocrinology and Metabolism Clinics of North America (2023) Vol. 52, Iss. 3, pp. 485-496
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top